{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T16:52:37Z","timestamp":1785775957478,"version":"3.56.0"},"reference-count":47,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T00:00:00Z","timestamp":1754870400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T00:00:00Z","timestamp":1754870400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100018904","name":"Beijing Xisike Clinical Oncology Research Foundation","doi-asserted-by":"publisher","award":["Y\u20102019AZZD\u201000680"],"award-info":[{"award-number":["Y\u20102019AZZD\u201000680"]}],"id":[{"id":"10.13039\/100018904","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81972484"],"award-info":[{"award-number":["81972484"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82272667"],"award-info":[{"award-number":["82272667"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Intl Journal of Cancer"],"published-print":{"date-parts":[[2026,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    This research (NCT04624711) evaluated the efficacy and safety of eribulin plus anlotinib in patients with HER2\u2010negative metastatic breast cancer (mBC) and explored the potential synergistic benefits of this combination. A total of 70 women with HER2\u2010negative breast cancer who had previously undergone anthracycline\u2010 or taxane\u2010based therapies were enrolled. Hormone receptor\u2010positive patients had also received CDK4\/6 (Cyclin\u2010dependent kinase 4\/6) inhibitor\u2010based endocrine therapy. All patients were treated with eribulin mesylate (1.4\u2009mg\/m\n                    <jats:sup>2<\/jats:sup>\n                    , administered intravenously on days 1 and 8) and anlotinib (12\u2009mg orally, once daily on days 1\u201314) in 21\u2010day cycles. The median progression\u2010free survival (mPFS) was 7.00\u2009months, with an objective response rate (ORR) of 50.00% and a disease control rate (DCR) of 94.29%. Patients with fewer than two visceral metastases exhibited a significantly longer median PFS than those with multiple visceral metastases (8.93\u2009months vs. 6.90\u2009months,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.0337). The most common treatment\u2010related adverse events (TRAEs) were neutropenia (67.14%) and leukopenia (68.57%), with 41.43% and 27.14% of patients experiencing grade 3\/4 hematologic toxicities, respectively. These findings suggest that the combination of eribulin and anlotinib demonstrated encouraging efficacy and a manageable safety profile, offering a potential therapeutic option for patients with HER2\u2010negative mBC.\n                  <\/jats:p>","DOI":"10.1002\/ijc.70079","type":"journal-article","created":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T13:50:31Z","timestamp":1754920231000},"page":"153-162","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["An open\u2010label phase\n                    <scp>II<\/scp>\n                    study: The efficiency and safety of anlotinib\u2009+\u2009eribulin in patients with\n                    <scp>HER2<\/scp>\n                    \u2010negative metastatic breast cancer"],"prefix":"10.1002","volume":"158","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-5459-298X","authenticated-orcid":false,"given":"Xinyu","family":"Wu","sequence":"first","affiliation":[{"name":"Department of Oncology Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology  Wuhan Hubei China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Qu","sequence":"additional","affiliation":[{"name":"Department of Oncology The Affiliated Wuxi People's Hospital of Nanjing Medical University  Wuxi China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yijia","family":"Hua","sequence":"additional","affiliation":[{"name":"Department of Oncology The First Affiliated Hospital of Nanjing Medical University  Nanjing Jiangsu China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongrong","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Oncology The First Affiliated Hospital of Nanjing Medical University  Nanjing Jiangsu China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Oncology The First Affiliated Hospital of Nanjing Medical University  Nanjing Jiangsu China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Liang","sequence":"additional","affiliation":[{"name":"Department of Oncology The First Affiliated Hospital of Nanjing Medical University  Nanjing Jiangsu China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunxiao","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Oncology The First Affiliated Hospital of Nanjing Medical University  Nanjing Jiangsu China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Oncology The First Affiliated Hospital of Nanjing Medical University  Nanjing Jiangsu China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Oncology The First Affiliated Hospital of Nanjing Medical University  Nanjing Jiangsu China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Oncology The First Affiliated Hospital of Nanjing Medical University  Nanjing Jiangsu China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3335-369X","authenticated-orcid":false,"given":"Yongmei","family":"Yin","sequence":"additional","affiliation":[{"name":"Department of Oncology The First Affiliated Hospital of Nanjing Medical University  Nanjing Jiangsu China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,8,11]]},"reference":[{"key":"e_1_2_13_2_1","unstructured":"CSCO.Breast Cancer Guidelines of Chinese Society of Clinical Oncology (CSCO).2024http:\/\/www.csco.org.cn\/cn\/index.aspx"},{"key":"e_1_2_13_3_1","volume-title":"Breast Cancer StatPearls","author":"Alkabban FM","year":"2023"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00911"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834"},{"key":"e_1_2_13_6_1","volume-title":"Survival rates for breast cancer","author":"Society AC","year":"2024"},{"key":"e_1_2_13_7_1","volume-title":"Breast Cancer \u2013 SEER 5\u2010year relative survival rates, 2014\u20132020: Surveillance Research Program","author":"SEER*Explorer","year":"2024"},{"key":"e_1_2_13_8_1","unstructured":"NCCN.NCCN Clinical Practice Guidelines in Breast Cancer (V.1.2025) vol. 2025.2025http:\/\/www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.14876"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60070-6"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.52.4892"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-018-0664-7"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13536"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-0939-x"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.3039"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-021-01356-3"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.e22518"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2023.106876"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.20892\/j.issn.2095-3941.2020.0463"},{"key":"e_1_2_13_20_1","unstructured":"TaoSLZ CX LiM LZ.PS3\u201006: a prospective phase 2 study on efficacy and safety of AK105 anlotinib combined with nab\u2010paclitaxel (nab\u2010P) as a first\u2010line therapy in patients (pts) with advanced triple\u2010negative breast cancer (TNBC) 2024 San Antonio Breast Cancer Symposium; 2024."},{"key":"e_1_2_13_21_1","doi-asserted-by":"crossref","unstructured":"MengH WangY LiS et al.P4\u201011\u201006: Neoadjuvant anlotinib plus nab\u2010paclitaxel based chemotherapy in patients with HER2\u2010negative breast cancer: a prospective single\u2010arm single\u2010center phase II clinical study 2024 San Antonio Breast Cancer Symposium; 2024.","DOI":"10.1158\/1557-3265.SABCS24-P4-11-06"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13392"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2016.122"},{"key":"e_1_2_13_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpha.2024.100984"},{"key":"e_1_2_13_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.32180"},{"key":"e_1_2_13_26_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0106131"},{"key":"e_1_2_13_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2014.80"},{"key":"e_1_2_13_28_1","doi-asserted-by":"publisher","DOI":"10.7555\/JBR.38.20240045"},{"key":"e_1_2_13_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01332-8"},{"key":"e_1_2_13_30_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-020-01709-5"},{"key":"e_1_2_13_31_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-13-1641"},{"key":"e_1_2_13_32_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.7476"},{"key":"e_1_2_13_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"e_1_2_13_34_1","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2019-0904-SA"},{"key":"e_1_2_13_35_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-198212000-00014"},{"key":"e_1_2_13_36_1","unstructured":"Common Terminology Criteria for Adverse Events (Ctcae) Version 5. 2017. vol. 2024.https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm#ctc_50"},{"key":"e_1_2_13_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2020.09.011"},{"key":"e_1_2_13_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100054"},{"key":"e_1_2_13_39_1","doi-asserted-by":"publisher","DOI":"10.1177\/17588359231204856"},{"key":"e_1_2_13_40_1","first-page":"236","article-title":"Efficiency and safety of Eribulin in patients with HER2 negative metastatic breast cancer: a real world study","volume":"43","year":"2023","journal-title":"J Nanjing Med Univ"},{"key":"e_1_2_13_41_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-016-0332-8"},{"key":"e_1_2_13_42_1","unstructured":"U.S. Food and Drug Administration.Drug Label: AVASTIN\u00ae (bevacizumab); vol. 2025 2009."},{"key":"e_1_2_13_43_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10585-021-10080-4"},{"key":"e_1_2_13_44_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa072113"},{"key":"e_1_2_13_45_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2013.69"},{"key":"e_1_2_13_46_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.28.0982"},{"key":"e_1_2_13_47_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-023-00671-z"},{"key":"e_1_2_13_48_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10456-019-09679-9"}],"container-title":["International Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ijc.70079","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ijc.70079","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ijc.70079","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T16:24:35Z","timestamp":1785774275000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ijc.70079"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,11]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,1]]}},"alternative-id":["10.1002\/ijc.70079"],"URL":"https:\/\/doi.org\/10.1002\/ijc.70079","archive":["Portico"],"relation":{},"ISSN":["0020-7136","1097-0215"],"issn-type":[{"value":"0020-7136","type":"print"},{"value":"1097-0215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,11]]},"assertion":[{"value":"2025-02-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}